SeaStar Medical Holding Corporation - Common Stock (ICU)
0.6022
-0.0061 (-1.00%)
NASDAQ · Last Trade: Sep 28th, 4:10 AM EDT
Detailed Quote
Previous Close
0.6083
Open
0.6000
Bid
0.5900
Ask
0.6100
Day's Range
0.5623 - 0.6150
52 Week Range
0.3054 - 4.490
Volume
3,738,630
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,854,560
Chart
About SeaStar Medical Holding Corporation - Common Stock (ICU)
SeaStar Medical Holding Corporation is a biotechnology company focused on developing innovative therapies to enhance the treatment of life-threatening kidney conditions. The company is primarily engaged in researching and creating advanced medical devices and technologies designed to improve the care of patients with acute kidney injury and other renal-related disorders. By leveraging its proprietary approach, SeaStar Medical aims to provide solutions that reduce the need for dialysis and improve patient outcomes, ultimately transforming the standard of care in nephrology. Read More
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded down 0.50% to 45,889.75 while the NASDAQ fell 1.38% to 22,187.39. The S&P 500 also fell, dropping, 0.94% to 6,575.35.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
DETROIT, MICHIGAN - July 11, 2025 ( NEWMEDIAWIRE ) - When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That’s particularly true regarding pediatric AKI – each year, about 4,000 children with AKI require continuous renal replacement therapy (RRT), with a mortality rate of approximately 51-58% . Many of those who survive experience long-term complications that can include chronic kidney disease and a lifetime of dialysis.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
DETROIT, MICHIGAN - June 27, 2025 ( NEWMEDIAWIRE ) - SeaStar Medical Holding Corp. (NASDAQ: ICU), the commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, has made a lot of inroads on that front with QUELIMMUNE. A humanitarian medical device, QUELIMMUNE treats pediatric patients with acute kidney injury or AKI due to sepsis or a septic condition. The QUELIMMUNE therapy received U.S. Food and Drug Administration approval in 2024 after clinical trials showed it could cut mortality in half from 50% to 25%.
DETROIT, MICHIGAN - June 27, 2025 ( NEWMEDIAWIRE ) - Dr. Kevin Chung, Chief Medical Officer at SeaStar Medical Holding Corporation (NASDAQ: ICU) and Dr. Stuart L. Goldstein, MD, from Cincinnati Children's Hospital Medical Center, were recently guests on Benzinga's All-Access.
